

DAFTAR PUSTAKA

1. International Agency for Research On Cancer. Latest world cancer statistics global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. [homepage on the Internet]. 2013 [cited 2013 Aug 5]. Available from: United Nation, World Health Organization Web site: http://http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf
2. Ferlay J, Steliarova-foucher E, Lortet-tieulent J, Rosso S, Coebergh Jww, Comber H, Forman D, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *European Journal of Cancer* 2013 2012; 49(1):1374-403.
3. Cooper N, Irvine L, Johnson S. *What cancer statistics are available, and where can I find them?*. <http://www.ncin.org.uk> (accessed 1 January 2014).
4. Dhillon PK. *Breast cancer factsheet*. South Asia Network for Chronic Disease, Public Health Foundation of India. Report number: 03.11.11, 2013.
5. Centers for Disease Control and Prevention. Cancer data and statistics. Atlanta : Centers for Disease Control and Prevention; 2012 (update May 16, 2012; cited Sept 10, 2012). Available from: <http://www.cdc.gov/cancer/dcpc/data/women.htm>
6. National Cancer Insitute. General informaton about breast cancer. Bethesda : USA. Gov ; 2012 (nodate). Available from : www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/page1

7. Blamey RW, Wilson ARM, Patrick J . screening for breast cancer in Dixon J
2nd ed A.B.C of breast disease . BMJ books London, 2000 : 33-7
8. Traditional Chinese Medicine from Wikipedia, the free encyclopedia.
http://en.wikipedia.org/wiki/Traditional_Chinese_medicine
9. Wang AM, Sha SH, Lesniak W, Schacht J. Tanshinone (Salviae miltiorrhizae
Extract) preparations attenuate aminoglycoside-induced free radical formation
in vitro and ototoxicity in vivo. American Society for Microbiology 2003;
47(6):1836-41.
10. Chen J, Chen T. Danshen (radix salvia miltiorrhizae), chapter 12 blood
invigorating and stasis removing herbs. Chinese medical herbology and
pharmacology. Art of medicine Press. www.AOMpress.com, copyright 2004
11. Song et al. Composition comprising Tanshinone compounds isolated from the
extract of Salviae miltiorrhizae radix for treating or preventing cognitive
dysfunction and the use thereof. United States Patent Application Publication.
Pub No. : US 2009/0312413 A1.Pub.Date : Dec.17, 2009.
12. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry,
pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol
. 2005;45(12):1345-59.
13. Lu Q, Zhang, Zhang, Chen J. Experimental study o the anti cancer mechanism
of tanshinone IIA against human breast cancer. International Journal of
molecular medicine 2009; 24:778-80.
14. Nizamutdinova IT, Gyeong WL, Kun HS. Tanshinone I effectively induces
apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-

- negative (MDA-MB-231) breast cancer cells. *International Journal of Oncology* 2008; 33:485-91.
15. Beral V, Banks E, Reeves G, Bull D. Breast cancer and hormone-replacement therapy: the Million Women Study. *The Lancet* 2003; 362(9392):1330-1.
16. Wang X, Wei Y, Yuan S, Liu G, Lu Y, et al. Potential anticancer activity of tanshinone IIA against human breast cancer, *International Journal of Cancer* 2005; 116(5):799-807.
17. Su CC, Lin YJ. Tanshinone IIA inhibits human breast cancer cells through increase Bax to Bcl-xL ratios. *International journal of molecular* 2008; 22(3):357-61.
18. Roomi MZ, Roomi NW, Ivanov V. Research article : Modulation of N-methyl-N-nitrosourea induced mammary tumors in Sprague-Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. *Breast Cancer Research* [serial on the Internet]. 2005 [cited 2012 Sep 5].;7(3) Available from: Matthias Rath Research, Cancer division Web site: <http://http://www.biomedcentral.com/content/pdf/bcr989.pdf>
19. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer J Clin* 2010; 60:277-300.
20. Kumar V, Abbas AK, Aster JC. *Robbins Basic Pathology*, 9th ed. Philadelphia: Elsevier Saunders; 2013.

21. Su CC, Chien SY, Kuo SJ, Chen YL, Cheng CY, Chen DR. *Tanshinone IIA inhibits human breast cancer MDA-MB-231 Cells by decreasing LC3-II, Erb-B2 and NF-kBp65*. Molecular Medicine report 2012; 5(4): 1019-22.
22. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-92.
23. Jatoi I, Chen BE, Anderson WF, et al. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007;25:1683-90.
24. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011; 223:307-17.
25. Tavassoli F, A DP. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the breast and female genital organs. WHO: Geneva, 2003;9-19.
26. Baretta G. Cancer treatment medical guide. 10th ed. Milan (Italy): Farmitalia Carlo Erba-Erbamont; 1991.
27. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
28. Azab S, Al-Hendy A. Signal transduction pathways in breast cancer – drug targets and challenges. In: Gunduz M, Gunduz E. Editors. Breast cancer – carcinogenesis, cell growth, and signaling pathways. Rijeka (Croatia): In Tech; 2011:109-11.

29. Jodi R, Viste, Sherry L, Myers, Singh B, Simko E. Feline mammary adenocarcinoma: tumor size as a prognostic indicator. *Can Vet J.* 2002; 43(1):33-7.
30. Bland KI, Beenken SW, Copeland III EM. The breast. In: Brunickardi FC, editor. *Schwartz's principles of surgery.* 8th ed. USA: McGraw-Hill; 2005: 453-91.
31. Conzen SD, Grushko TA, Olopade OI. Cancer of the breast. In: Devita Jr VT, editor. *Cancer: principles and practice of oncology.* 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1415-49.
32. Iglehart JD, Smith BL. Diseases of the breast. In: Townsend CM, editor. *Sabiston textbook of surgery.* 18th ed. Philadelphia : Elsevier-Saunders; 2007.
33. Bland KI, Beenken SW, Copeland III EM. The breast. In: Brunickardi FC, editor. *Schwartz's principles of surgery.* 8th ed. USA: McGraw-Hill; 2005: 453-91.
34. Rosai J. *Rosai and Ackerman's surgical pathology.* 10th ed. Philadelphia : Elsevier Inc, 2011.
35. Sausville EA, Longo DL. Principles of cancer treatment. In : Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. *Harrison's principles of internal medicine (book on CD-ROM).* 15th ed. New York; McGraw-Hill;2001.
36. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agent targeting signal molecules and cancer cell environment : challenges

- for drug development. *Journal of the National Cancer Institute* 1999 Aug 4;91(15):1281-7
37. Abbas A, Lichtman AH, Pillai S. *Cellular and molecular immunology*. 6thed. Philadelphia: Elsevier-Saunders; 2007.
38. Kumar, Abbas, Fausto, Mitchell. *Robbins basic pathology* 8th ed. Philadelphia: Elsevier Saunders; 2007.
39. Cruse JM, Lewis RE. *Atlas of immunology*. 2nd ed. Boca Raton, Florida: CRC Press; 2004.
40. The Wikipedia free encyclopedia. Apoptosis. Adelaide: Wikipedia Foundation Inc; 2007. p 1-10. Available from:
[URL:http://en.wikipedia.org/wiki/Apoptosis](http://en.wikipedia.org/wiki/Apoptosis).
41. Brewer DS. *Modelling the p53 gene regulatory network* (thesis). London: University of London, 2006;297.
42. Vogelstein B, Lane D, Levine A. Surfing the p53 network. *Nature*, 408(6810):307–10, 2000.
43. Lane DP. Cancer. p53, guardian of the genome. *Nature*, 358(6381):15–16, Jul 1992.
44. Soussi T, Dehouche K, and Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum Mutat*, 15(1):105–13, 2000.
45. Bode AM and Dong Z. Post-translational modification of p53 in tumorigenesis. *Nat Rev Cancer*, 4(10):793–805, Oct 2004.

46. Hickman E, Moroni M, and Helin K. The role of p53 and pRB in apoptosis and cancer. *Curr Opin Genet Dev*, 12(1):60–6, 2002.
47. Harris SL, Levine J. The p53 pathway: positive and negative feedback loops. *Oncogene*, 24(17):2899–2908, Apr 2005.
48. Clark AR, Gledhill S, Hooper ML, Bird C.C, and Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. *Oncogene*, 9(6):1767–73, Jun 1994.
49. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, and Hall PA. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. *Cancer Res*, 54(3):614–17, Feb 1994.
50. Wahl G and Carr A. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. *Nat Cell Biol*, 3(12):E277–86, 2001.
51. Sherr C and Weber J. The ARF/p53 pathway. *Curr Opin Genet Dev*, 10(1):94–9, 2000.
52. Vousden KH. p53: death star. *Cell*, 103(5):691–4, Nov 22 2000.
53. Wahl G, Linke S, Paulson T, and Huang L. Maintaining genetic stability through TP53 mediated checkpoint control. *Cancer Surv*, 29:183–219, 1997.
54. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. *Nature*, 404(6773):42–9, 2000.

55. Offer H, Zurer I, Banfalvi G, Reha'k M, FalcovitzA, MilyavskyM, Goldfinger N, and Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. *Cancer Res*, 61(1):88–96, 2001.
56. Balint E and Vousden K. Activation and activities of the p53 tumour suppressor protein. *Br J Cancer*, 85(12):1813–23, 2001.
57. Endokrin-related cancer, Society for endocrinology and european society of endocrinology. Available from :
<http://erc.endocrinologyjournals.org/content/15/1/11/F1.expansion.html>
58. T M Murphy, A S Perry, and M Lawler. Review: The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer
Endocr Relat Cancer 2008 15 11-25 (Published 1 March 2008)
59. Herbal Expert Working Group of the Pan-European Federation of TCM Societies(PEFOT). Danshenform: High quality traditional Chinese herbal medicinal product intended to be registered as a traditional herbal medicinal product in the European Union. Beijing : China Medico-Pharmaceutical Science & Technology Publishing House; 2004.
60. Wang BQ. *Salvia miltiorrhiza*: chemical and pharmacological review of a medicinal plant. *J Med. Plant Res*. Vol.4(25); 2813-20.
61. Liu F, Yu G, Wang G, Liu H, Wu X, wang Q, et al. An NQO1-Initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer. *Plos ONE Jurnal.Pone* 2012; 7(7):e42138.

62. Gay WI. Methods of animal experimentation. 1th ed. New York ; Academic Pres Inc, 1965.
63. Perhimpunan Dokter Spesialis Patologi Indonesia(IAPI). Pedomen penanganan bahan pemeriksaan untuk histopatologi. 1th ed. Jakarta, 2008.
64. Prophet E, Mills B, Arrington JB, Sobin LH. Laboratory methods in histotechnology. 1th ed. Washington DC : American Registry of Pathologu, 1994.
65. Lee CY, Sher HF, Chen HW, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. *Mol Cancer Ther* 2008;7:3527-3538. Published online November 11, 2008. Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-07-2288. Access the most recent supplemental material at:
<http://mct.aacrjournals.org/content/suppl/2008/11/04/7.11.3527.DC1.html>
Downloaded from mct.aacrjournals.org on March 12, 2012
Copyright © 2008 American Association for Cancer Research
66. Qureshi A, Pervez S. Allred scoring for ER reporting and it's impact in clearly distinguishing ER negative from ER positive breast cancers. *J Pak Med Assoc* 2010; 60(5):350-3.
67. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by F-FDG-microPET or external caliper. *BMC Medical Imaging*, 2008 ;8(16): 1-9